✨ Free AI Report
ALK-Abelló A/S: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ALK-Abelló A/S
Company Research

ALK-Abelló A/S: Business Overview, Financials & Competitive Analysis

ALK-Abelló A/S scores 7/10 on the AskCyborg Cyborg Score (Strong). Dominant player in allergy immunotherapy with expanding product portfolio and emerging anaphylaxis solutions targeting a growing global allergy patient population. Market-leading position in a specialized niche with strong R&D focus and established global presence across 46 countries. Recent regulatory approval for EURneffy needle-free anaphylaxis treatment demonstrates innovation pipeline strength. Strategic.

What is ALK-Abelló A/S's industry? ALK-Abelló A/S (alk.net) operates in Specialty Pharmaceuticals - Allergy Immunotherapy. AskCyborg classifies ALK-Abelló A/S under Specialty Pharmaceuticals - Allergy Immunotherapy in its company registry.

ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. ...

7/ 10Strong

Cyborg Score thesis

Dominant player in allergy immunotherapy with expanding product portfolio and emerging anaphylaxis solutions targeting a growing...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Allergy Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest ALK-Abelló A/S Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for ALK-Abelló A/S

AskCyborg analysts argue the bull and bear cases for ALK-Abelló A/S across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ALK-Abelló A/S OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

ALK-Abelló A/S Overview

Pro stress-test →

ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. The company develops, produces, and markets allergy immunotherapy and anaphylaxis treatments.

Strategic Profile

Pro stress-test →

ALK is the world leader in allergy immunotherapy, providing products as injections, sublingual drops and sublingual tablets. The company offers a digital ecosystem platform connecting allergy sufferers with diagnostic solutions and emergency treatments for anaphylaxis.

Competitive Landscape

Pro stress-test →

ALK holds the leading market position in allergy immunotherapy globally. Primary competition comes from pharmaceutical companies developing alternative allergy treatments and immunotherapy approaches. The company maintains strategic partnership with Torii Pharmaceutical for regional product development including GRAZAX, CEDARCURE, and MITICURE.

Industry Context

ALK-Abelló A/S operates in Specialty Pharmaceuticals - Allergy Immunotherapy.

Key facts

Founded: 1923 · Headquarters: Horsholm, Denmark · Employees: 2900 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for ALK-Abelló A/S.

  • Received positive recommendation for EURneffy 1 mg, a needle-free anaphylaxis treatment for children (January 2026)
  • Company strategy focuses on sublingual immunotherapy tablets for grass pollen, ragweed, and house dust mite allergies
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Annual report 2025 presentation scheduled
  • January 2026EURneffy needle-free anaphylaxis treatment receives positive regulatory recommendation
  • +1 moreTrack every material event for ALK-Abelló A/S as it happens. Explore monitoring →
Get alerted when ALK-Abelló A/S has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kytopen/Oral ImmunotherapyEuropean allergy immunotherapy competitor→ASIT biotech PlatformImmunotherapy innovation for allergies→Torii Collaboration ProductsRegional immunotherapy partnership→

Compare ALK-Abelló A/S with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ALK-Abelló A/S operates in Specialty Pharmaceuticals - Allergy Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Allergy Immunotherapy research →
NEW · MCP server

Ask your AI assistant about ALK-Abelló A/S

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ALK-Abelló A/S and its top competitor on Cyborg Score”
“What did ALK-Abelló A/S do this quarter?”
“Is ALK-Abelló A/S a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does ALK-Abelló A/S do?+
ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. ...
What is ALK-Abelló A/S's Cyborg Score?+
ALK-Abelló A/S has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ALK-Abelló A/S's main competitors?+
Named competitors include Kytopen/Oral Immunotherapy, ASIT biotech Platform, Torii Collaboration Products. The full competitive landscape is in the AskCyborg report.
How can I get the full ALK-Abelló A/S research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ALK-Abelló A/S research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ALK-Abelló A/S over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.